Unleashing the Sensitivity of Single Molecule Counting (SMC™) Technology
Ultrasensitive SMC™ technology, originally developed by Singulex®, Inc., provides an indispensable tool in the researcher’s arsenal to help them move novel biology forward, fueling the discovery and development of new therapeutics.
Merck now offers the power of SMC™ technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through the Research-Use-Only SMCxPRO™ and Erenna® immunoassay systems, immunoassay kits, reagents, and custom services.
Previously Undetectable, Now Quantified. One Molecule at a Time.
SMC™ Single Molecule Counting (SMC™) technology enables precise measurement of molecules at levels previously undetectable, for unprecedented biomarker insights.
Scientists familiar with traditional immunoassays, such as ELISAs, know that sensitivity, matrix effects, and dynamic range affect how they make measurements—or if they can make them at all.
Combining a traditional immunoassay workflow with patented SMC™ technology enables the detection of low-abundance biomarkers, such as proteins and nucleic acids, with unparalleled sensitivity and accuracy, capturing concentrations down to the femtogram/mL level. Researchers can now detect, and monitor changes in, extremely low levels of established disease biomarkers such as cardiac troponin I and cytokines.
At femtograms per mL, it was undetectable…
Learn why Dr. Erika Cline switched to Singulex Erenna® assays.